Physician

Narasimha Rao Boorgu, M.D.

According to 2025 Medicare claims, Narasimha Boorgu, M.D. (NPI: 1043218928) practices nephrology in the Florence-Muscle Shoals, AL market, with the plurality of this provider's patient population coming from Lauderdale, AL. This provider's primary affiliated billing organization is N RAO BOORGU MD PC (NPI: 1780641951; TIN: 630794660) and primary practice location at 35630-5707. Boorgu is affiliated with the Huntsville ACO (ACO ID: A3579), participating under the MSSP model.

Boorgu's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 528 traditional Medicare patients, billed 35,610 HCPCS/CPT codes, and received $261,994 in Medicare payments. The top billing code was 80053 (Blood test, comprehensive group of blood chemicals). Part D data shows 7,978 prescription claims across 867 beneficiaries totaling $2,095,009 in drug costs, led by Ozempic (Semaglutide). DME data shows 239 claims. Open Payments data shows 87 records totaling $1,706. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has fallen sharply in recent years, from $608,880 to $261,994. In contrast, Part D prescription costs have moved sharply higher in recent years, from $922,223 to $2,095,009. For DME billing, this smaller-volume category rose steadily, from $13,488 to $56,380.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	1,364	43,392	$608,880
2016	1,322	61,637	$606,727
2017	1,333	105,509	$683,895
2018	1,175	96,645	$685,685
2019	1,074	141,674	$701,796
2020	846	112,039	$486,798
2021	745	86,003	$498,438
2022	637	40,158	$387,655
2023	556	28,648	$296,584
2024	528	35,610	$261,994

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	750	7,413	$922,223
2016	767	7,179	$1,031,244
2017	811	7,997	$892,625
2018	824	8,832	$1,163,126
2019	794	8,335	$1,673,401
2020	720	8,078	$1,021,182
2021	774	7,830	$1,136,999
2022	842	7,805	$1,563,948
2023	875	7,814	$2,211,971
2024	867	7,978	$2,095,009

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	146	485	$22,043
2016	126	525	$29,646
2017	66	377	$14,085
2018	54	299	$7,896
2019	25	206	$4,709
2020	30	189	$6,889
2021	28	282	$25,034
2022	16	231	$25,306
2023	36	267	$35,146
2024	22	239	$42,935

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
80053	Blood test, comprehensive group of blood chemicals	450	1,119	$10
36415	Insertion of needle into vein for collection of blood sample	445	1,204	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	451	1,171	$8
84100	Phosphate level	444	1,101	$5
84550	Uric acid level, blood	444	1,099	$4

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Ozempic	Semaglutide	325	11,535	$377,863
Mounjaro	Tirzepatide	315	10,286	$376,700
Kerendia	Finerenone	178	7,848	$162,134
Farxiga	Dapagliflozin Propanediol	162	7,730	$140,571
Repatha Sureclick	Evolocumab	181	6,946	$130,236

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
A4239	Supply allowance for non-adjunctive, non-implanted continuous glucose monitor (cgm), includes all supplies and accessories, 1 month supply = 1 unit of service	N	22	87	$39,707
J7502	Cyclosporine, oral, 100 mg	N	N/R	13	$1,295
J7517	Mycophenolate mofetil, oral, 250 mg	N	N/R	25	$491
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	41	$489
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	21	$358

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	87	$1,706	Amgen Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Narasimha Rao Boorgu, M.D.?

Tedicare shows public-source Medicare data for Narasimha Rao Boorgu, M.D. (NPI 1043218928), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Narasimha Rao Boorgu, M.D. have ACO affiliation data?

Narasimha Rao Boorgu, M.D. is shown with ACO affiliation data for Huntsville ACO (MSSP, ACO ID A3579).

What billing organization is linked to Narasimha Rao Boorgu, M.D.?

Narasimha Rao Boorgu, M.D. is linked to N RAO BOORGU MD PC (billing NPI 1780641951) in the available physician profile data.

Does Narasimha Rao Boorgu, M.D. have Open Payments data?

Narasimha Rao Boorgu, M.D. has 87 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.